Table of Contents Author Guidelines Submit a Manuscript

Analytical Cellular Pathology in Lung Cancer Drug Discovery and Development

Call for Papers

The discovery of new cancer biomarkers plays an indispensable role in the detection of lung cancer. Indeed, the biomarker can be used in screening and development of the new strategy to fight against lung cancer. Cancer is not a single disease, and there are several genetic and epigenetic alterations. The identification of molecular changes in the lung tumor cells can be used in the distinguishing and individual alteration of cancer cell from nontumor cells. It thus can be driving the researchers to further predict the pathological behavior and progress of lung tumor. This can help the scientists to understand the molecular profile of this cancer type; it, in turn, can be extremely useful in drug discovery in identification of lung cancer-associated genes and their protein products. The new technologies and tools that enable identifying the molecular biomarker are needed urgently.

Potential topics include but are not limited to the following:

  • Validation of new lung cancer biomarker
  • New analytical tools in lung cancer drug discovery
  • The identification of molecular changes in lung tumor cells
  • Methods of screening new targets in lung cancer cells
  • In situ detection of lung cancer stem cells
  • In silico tool used as approach to discover new biomarkers in lung cancer

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 23 March 2018
Publication DateAugust 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Guest Editors